CDSCO Panel Approves Novartis Healthcare's Protocol Amendment to study Iptacopan Dr. Divya Colin3 May 2025 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has approved the protocol...
Novartis Healthcare Gets CDSCO Panel Nod To study Anti-cancer Drug Asciminib Dr. Divya Colin6 April 2025 3:30 AM ISTNew Delhi: Pharmaceutical major Novartis Healthcare has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
CDSCO Panel Approves Novartis Protocol Amendment Proposal fo Ianalumab study Dr. Divya Colin2 April 2025 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
Generate PMS data to assess patient safety : CDSCO Panel Tells Novartis Healthcare on additional indications of Secukinumab Dr. Divya Colin17 March 2025 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major...
Inclisiran be sold by retail under prescription of cardiologist only: CDSCO panel tells Novartis Healthcare Dr. Divya Colin7 Dec 2024 5:30 PM ISTNew Delhi: Rejecting the drug major Novartis Healthcare's proposal for amendment in the warning statement of Inclisiran Solution for injection, the...
Novartis Healthcare gets CDSCO Panel nod to study Iptacopan Dr. Divya Colin24 Nov 2024 5:45 PM ISTNew Delhi: The drug major Novartis Healthcare has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Novartis Healthcare Gets CDSCO Panel Nod to Study Asciminib Filmcoated Tablets Dr. Divya Colin28 July 2024 6:00 PM ISTNew Delhi: Suggesting to add more government sites, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization...
CDSCO Panel approves Novartis Healthcare for selective use of Secukinumab dose up to 300 mg Dr. Divya Colin14 July 2024 6:00 PM ISTNew Delhi: Reviewing the justification presented by the drug major Novartis Healthcare for the monoclonal antibody Secukinumab, the Subject Expert...
Will Novartis continue business in India? Global Drug major strategic review to decide Ruchika Sharma17 Feb 2024 2:16 PM ISTDrug major Novartis AG has announced a strategic review of Novartis India Ltd, a public company listed on the BSE.The strategic review will include an...
JB Pharma enters Opthalmology space, signs Rs 1,089 crore deal with Novartis for 10 brands Ruchika Sharma20 Dec 2023 11:14 AM ISTNew Delhi: JB Chemicals & Pharmaceuticals Ltd (JB Pharma) has announced that the Company has inked a trade mark licence agreement along with...
Novartis Healthcare gets CDSCO panel nod to market anti cancer drug Dabrafenib Susmita Roy19 Feb 2022 5:49 PM ISTNew Delhi: In a significant development, pharmaceutical major Novartis Healthcare has got a go ahead from the Subject Expert Committee (SEC) of the...
Allegations of Pharma Collusion for Fixing Price of Vidagliptin: Court dismisses Abbotts plea again CCI Probe Meghna A Singhania25 Nov 2018 8:18 PM ISTNew Delhi: Quashing the petition filed by leading drug maker Abbott, that wanted to stall the CCI probe into alleged carterlisation to fix the prices...
